Chemours (CC Quick QuoteCC - Free Report) reported $1.54 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 3%. EPS of $0.21 for the same period compares to $0.20 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.54 billion, representing a surprise of -0.11%. The company delivered an EPS surprise of -19.23%, with the consensus EPS estimate being $0.26.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Thermal & Specialized Solutions: $510 million compared to the $492.44 million average estimate based on four analysts. The reported number represents a change of -8.9% year over year.
• Net Sales- Titanium Technologies: $680 million compared to the $696.28 million average estimate based on four analysts. The reported number represents a change of +11.1% year over year.
• Net Sales- Other Non-Reportable Segment: $13 million compared to the $11.26 million average estimate based on four analysts.
• Net Sales- Advanced Performance Materials: $337 million versus the four-analyst average estimate of $341.65 million. The reported number represents a year-over-year change of +8.4%.
• Adjusted EBITDA- Titanium Technologies: $85 million compared to the $72.3 million average estimate based on four analysts.
• Adjusted EBITDA- Corporate and Other: $-46 million compared to the $-39.21 million average estimate based on four analysts.
• Adjusted EBITDA- Thermal & Specialized Solutions: $136 million compared to the $134.36 million average estimate based on four analysts.
• Adjusted EBITDA- Advanced Performance Materials: $24 million versus $24.69 million estimated by four analysts on average.
• Adjusted EBITDA- Other Non-Reportable Segment: $1 million versus $1.61 million estimated by three analysts on average.

View all Key Company Metrics for Chemours here>>>

Shares of Chemours have returned -1.3% over the past month versus the Zacks S&P 500 composite's -0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.